Atezolizumab treats urothelial carcinoma by targeting PD-L1, a protein on the surface of tumor cells. PD-L1 binds to PD-1 receptors on T cells, preventing the immune system from attacking cancer cells. This evidence concerns the gene CD274 and urothelial carcinoma.